Current Report
Filed: 2026-01-08
Key Insights
- Xilio Therapeutics, Inc. reported its estimated cash and cash equivalents as of December 31, 2025 were approximately $137.5 million, indicating a strong financial position.
- The company announced the appointment of Sara M. Bonstein as the new chair of the Board, replacing the retiring Paul Clancy, which represents a leadership change.
- Xilio Therapeutics is an emerging growth company, which may provide flexibility in financial reporting and compliance requirements.